A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) (SKYLINE)
A Phase III, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease
Sponsor: Hoffmann-La Roche
Terminated
Decision to terminate development of gantenerumab for treatment of people at risk for or at earliest stages of Alzheimer disease (AD) following results of a pre-planned analysis of safety \& efficacy of gantenerumab in Graduate I\&II (WN29922/WN39658).
Other terminated trials from Hoffmann-La Roche
Other Alzheimers Disease trials with similar outcome
Listed as NCT05256134, this PHASE3 trial focuses on Alzheimers Disease and remains terminated or withdrawn. Sponsored by Hoffmann-La Roche, it has been updated 15 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Jul 2025 [monthly]
Terminated PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Terminated PHASE3
▶ Show 10 earlier versions
-
May 2023 — Jul 2024 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Jan 2023 — May 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .